ESMO 2023 | ESMO 2023 highlights in the treatment of ovarian cancer

Benoit You, MD, PhD, Lyon University Hospital, Lyon, France, discusses the revolution in the treatment of ovarian cancer over the past year. Immunotherapy in addition to standard paclitaxel and carboplatin chemotherapy has improved overall and progression-free survival for patients, such that now the standard therapy is changing. Dr You also highlights the DUO-E trial (NCT04269200) for its relevance in the use of PARP inhibitors for particular patient subgroups, increasing overall and potentially progression-free survival. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.